Hedlin Gunilla
Department of Women's and Children's Health, Karolinska Institutet, Stockholm, Sweden; Centre for Allergy Research, Karolinska Institutet, Stockholm, Sweden.
Pediatr Allergy Immunol. 2014 Mar;25(2):111-21. doi: 10.1111/pai.12112. Epub 2013 Sep 16.
The majority of children with asthma have mild or moderate disease and can obtain adequate control of symptoms through avoidance of triggering factors and/or with the help of medications. There is still a group of children with severe asthma in whom symptom control is poor depending either on identifiable aggravating factors or on true therapy resistance. These children have a poor quality of life and are limited by the severity of their disease. There is a need for a staged approach to the assessment and treatment of this small but vulnerable and resource-consuming group. The current review will provide an overview of a possible standardized approach to characterize this heterogeneous group of severely sick children including some newly developed ways of assessing asthma severity and potentialities of new asthma therapies. Furthermore, the umbrella term 'problematic severe asthma' is described. The term encompasses children whose severe asthma is due to identifiable exacerbating factors, as well as children who are resistant to any conventional therapeutic approach. Characteristics of these two groups of children are described, as are possible biomarkers and current and emerging diagnostic tools for allergy evaluation. Some recent advances and future possibilities for treatment of severe asthma are also presented in this review.
大多数哮喘儿童患有轻度或中度疾病,通过避免触发因素和/或借助药物治疗能够充分控制症状。仍有一组重度哮喘儿童,无论是否存在可识别的加重因素或真正的治疗抵抗,其症状控制都很差。这些儿童生活质量差,受到疾病严重程度的限制。对于这一小部分虽数量不多但脆弱且耗费资源的群体,需要采用分阶段的方法进行评估和治疗。本综述将概述一种可能的标准化方法,以对这一异质性的重症患儿群体进行特征描述,包括一些新开发的评估哮喘严重程度的方法以及新哮喘疗法的潜力。此外,还描述了“疑难重症哮喘”这一统称。该术语涵盖了重度哮喘归因于可识别加重因素的儿童,以及对任何传统治疗方法均有抵抗的儿童。描述了这两组儿童的特征、可能的生物标志物以及用于过敏评估的现有和新兴诊断工具。本综述还介绍了重度哮喘治疗方面的一些最新进展和未来可能性。